Best practices for the Multidisciplinary Management of NHL using Antibody Therapeutics
Podcast
Post-Test/Evaluation

Questions marked with a * are required
23%
Contact Information
Credentials/Degree (MD, DO, RN, etc.)
Date of  Participation
Geoffrey is a 69-year-old man who you previously diagnosed as having stage IV non-GCB DLBCL with an IPI of 4. You administered three cycles of R-CHOP, noting slowly responsive disease on CT, whereupon you administered three more cycles of R-CHOP. Repeat biopsy, however, confirmed primary refractory disease. As second-line therapy, you then prescribed two cycles of polatuzumab vedotin and rituximab as bridging treatment for Geoffrey, followed by fludarabine/cyclophosphamide lymphodepletion and CD19-directed CAR T-cell treatment with axi-cel. Geoffrey continues to progress. What is the next best step for this patient? 
Which of the following statements best describes the findings of the phase 2 LOTIS-2 trial investigating loncastuximab tesirine in patients with R/R DLBCL? 
Martin is a 64-year-old male who has primary refractory advanced stage GCB DLBCL.   He has previously been treated with R-DA-EPOCH, followed by Pola-BR and axi-cel. You determine now that he may be a viable candidate for a bispecific antibody. When counseling the patient about adverse events related to treatment with this class of agents, your discussion should include which of the following? 
Powered by QuestionPro